Studie AMG552- Fortitude 102

AMG552- Fortitude 102

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) (Phase 1 nur in USA, Phase 3 weltweit)

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung aktiv

Unbekannt / Unbekannt

Chemo